摘要
目的探讨卡培他滨和曲妥珠单抗联合全脑放疗治疗人类表皮生长因子受体2(HER2)阳性乳腺癌脑转移患者的临床疗效。方法回顾性分析笔者所在医院2004年1月至2012年1月期间收治的60例HER2阳性乳腺癌脑转移患者的临床资料,其中使用卡培他滨和曲妥珠单抗联合全脑放疗患者32例作为观察组,使用卡培他滨和顺铂联合全脑放疗患者28例作为对照组。对比2组患者治疗后的疾病控制率、毒副反应发生率及生存率。结果观察组患者治疗后的疾病控制率和生存率明显高于对照组(P<0.05),毒副反应发生率则显著低于对照组(P<0.05)。结论卡培他滨和曲妥珠单抗联合全脑放疗治疗HER2阳性乳腺癌脑转移患者安全、有效,值得临床推广使用。
Objective To investigate the curative effects of capecitabine and hessaitin combined with whole brain radiotherapy for treatment the HER2 positive breast cancer with brain metastasis. Methods The clinical data of 60 cases HER2-positive breast cancer patients with brain metastasis in our hospital in January 2004 to January 2012 were retrospectively analyzed. The 32 cases of observe group were treated by using capecitabine and herceptin combined with whole brain radiotherapy, and the 28 cases of control group were treated by using capecitabine and cisplatin combined with whole brain radiotherapy. The disease control rate, toxicity rate, and survival rate were evaluated. Results Compared with the control group, the disease control rate, toxicity rate, and survival rate were all better in observe group（P〈0.05）. Conclusion The capecitabine and hessaitin combined with whole brain radiotherapy for treating patients with HER 2 positive brest cancer transferred to brain are effect and safe.
出处
《中国普外基础与临床杂志》
CAS
2015年第4期447-450,共4页
Chinese Journal of Bases and Clinics In General Surgery
关键词
HER2阳性乳腺癌
卡培他滨
曲妥珠单抗
脑转移
临床疗效
HER 2 positive brest cancer
Capecitabine
Trastuzumab
Whole brain radiotherapy
Brain metastasis
Curative effect
